Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Response to ToleroMune Ragweed
NCT01361412Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Mar 2011
- Primary completion
- Sep 2011
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ragweed-spire in ragweed allergy (5 arms), sponsored by NIOX Group. Primary endpoint: Identification of potential plasma biomarkers of response to peptide immunotherapy at 6 months. Started Mar 2011; status: completed.
02
Drugs
ragweed-spire
03
Conditions
ragweed allergy
Beyond the preview
Go deeper on NCT01361412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361412.